Alpha Tau Medical (DRTS) CFO reports open-market sale of 17,500 shares

Rhea-AI Filing Summary

Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi reported selling a total of 17,500 Ordinary Shares in open-market transactions. The Form 4 shows two sales on June 23, 2026, at prices of $10.0004 and $9.47 per share. These are non-derivative transactions in the company’s common equity.

Insights

Equity analyst

CFO’s Form 4 shows routine-scale open-market share sales.

The filing shows Alpha Tau Medical CFO Levy Raphi sold 17,500 Ordinary Shares in two open-market trades, at prices of $10.0004 and $9.47 per share on June 23, 2026. All transactions involve non-derivative common equity.

There are no derivative exercises, tax withholdings, or gifts disclosed; derivative positions are listed as empty, so this snapshot only reflects direct share sales. The net effect is a 100% net-sell for the reported transactions, but the excerpt does not state what portion of his overall holdings this represents.

Subsequent company filings may provide additional context on total insider ownership levels or any future transactions, which would help investors interpret how these sales fit into the broader pattern of insider activity over time.

Insider Trade Summary 10b5-1

Net Seller: 17,500 shares

Net Sell 2 txns

Insider Levy Raphi

Role Chief Financial Officer

Sold 17,500 shs ($167K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	15,000	$9.47	$142K
Sale	Ordinary Shares	2,500	$10.0004	$25K

Holdings After Transaction: Ordinary Shares — 130,180 shares (Direct)

Key Figures

Total shares sold: 17,500 shares First trade size: 2,500 shares First trade price: $10.0004 per share +3 more

6 metrics

Total shares sold 17,500 shares Aggregate open-market sales reported in Form 4

First trade size 2,500 shares Ordinary Shares sold in one transaction

First trade price $10.0004 per share Price for 2,500-share sale on June 23, 2026

Second trade size 15,000 shares Ordinary Shares sold in second transaction

Second trade price $9.47 per share Price for 15,000-share sale on June 23, 2026

Net buy/sell shares -17,500 shares Transaction summary net-buy-sell direction net-sell

Key Terms

Ordinary Shares, open-market sale, non-derivative, transaction code “S”, +1 more

5 terms

Ordinary Shares financial

"The filing shows Alpha Tau Medical CFO Levy Raphi sold 17,500 Ordinary Shares in two open-market trades"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open-market sale financial

"reported selling a total of 17,500 Ordinary Shares in open-market transactions"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"These are non-derivative transactions in the company’s common equity"

transaction code “S” financial

"Both entries use transaction code “S,” which indicates a sale in an open-market or private transaction"

net-sell financial

"The transaction summary reports 17,500 shares sold, zero shares bought, and a net-sell direction"

FAQ

What did Alpha Tau Medical (DRTS) CFO Levy Raphi report in this Form 4?

Levy Raphi reported selling 17,500 Ordinary Shares of Alpha Tau Medical. The sales were open-market transactions in the company’s common equity, disclosed as non-derivative trades in this Form 4 filing with detailed share counts and prices.

How many Alpha Tau Medical (DRTS) shares did the CFO sell and at what prices?

The CFO sold 17,500 Ordinary Shares in total. One trade covered 2,500 shares at $10.0004 per share, and another covered 15,000 shares at $9.47 per share, both executed as open-market sales on the same reporting date.

Were the Alpha Tau Medical (DRTS) CFO’s transactions in derivatives or common shares?

All reported transactions involved non-derivative Ordinary Shares, meaning common equity. The derivative summary in the data is empty, indicating no listed option exercises, warrant conversions, or other derivative activities associated with this specific Form 4 event.

Does this Alpha Tau Medical (DRTS) Form 4 show net buying or net selling by the CFO?

The Form 4 shows net selling activity. The transaction summary reports 17,500 shares sold, zero shares bought, and a net-sell direction, reflecting two open-market sale transactions without any offsetting purchases in the reported period.

What type of transaction code appears in the Alpha Tau Medical (DRTS) Form 4?

Both entries use transaction code “S,” which indicates a sale in an open-market or private transaction. This code, combined with the stated prices per share, confirms that the reported trades are straightforward open-market sales of Ordinary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 10:17 AM Accepted by SEC EDGAR 06/25/2026 - 10:16 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levy Raphi

(Last) (First) (Middle)

C/O ALPHA TAU MEDICAL

PO BOX 45044

(Street)

JERUSALEM 9777605

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alpha Tau Medical Ltd. [ DRTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/23/2026	06/24/2026	S		15,000	D	$9.47	132,680	D
Ordinary Shares	06/23/2026	06/24/2026	S		2,500	D	$10.0004	130,180	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	Raphi Levy	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)